Antiangiogenic therapy has been shown to reverse resistance to ICIs and enhance treatment effects, offering significant survival benefits in advanced TNBC patients.13,18 This enhancement is mediated by promoting CD8+ T cell infiltration and activation within the tumor microenvironment, alongside antiangiogenic-induced PD-L1 upregulation.22,23 In our study, the combination of apatinib with camrelizumab and chemotherapy further supported the notion that antiangiogenic therapy can augment the efficacy of immunotherapy, demonstrating promising results in early or locally advanced TNBC. This evidence concerns the gene CD8A and neoplasm.